Versor Investments LP Sells 2,671 Shares of Haemonetics Corporation $HAE

Versor Investments LP trimmed its position in Haemonetics Corporation (NYSE:HAE) by 47.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,003 shares of the medical instruments supplier’s stock after selling 2,671 shares during the quarter. Versor Investments LP’s holdings in Haemonetics were worth $224,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in HAE. Citigroup Inc. increased its position in shares of Haemonetics by 87.3% in the first quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock valued at $39,755,000 after acquiring an additional 291,574 shares during the period. MetLife Investment Management LLC grew its stake in shares of Haemonetics by 448.0% in the first quarter. MetLife Investment Management LLC now owns 316,542 shares of the medical instruments supplier’s stock worth $20,116,000 after purchasing an additional 258,776 shares during the last quarter. Nuveen LLC bought a new stake in shares of Haemonetics in the first quarter worth about $10,340,000. AQR Capital Management LLC increased its holdings in Haemonetics by 591.6% during the 1st quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock valued at $10,931,000 after purchasing an additional 149,325 shares during the period. Finally, Raymond James Financial Inc. raised its position in Haemonetics by 60.6% during the 1st quarter. Raymond James Financial Inc. now owns 390,856 shares of the medical instruments supplier’s stock valued at $24,839,000 after purchasing an additional 147,492 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $67.66 on Friday. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $94.99. The firm has a market capitalization of $3.26 billion, a P/E ratio of 20.69, a P/E/G ratio of 0.91 and a beta of 0.43. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. The business has a fifty day simple moving average of $51.25 and a two-hundred day simple moving average of $62.02.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same period last year, the business earned $1.12 EPS. Haemonetics’s quarterly revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, equities analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of recent analyst reports. Raymond James Financial lowered Haemonetics from a “strong-buy” rating to an “outperform” rating and cut their price objective for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. BTIG Research lifted their target price on shares of Haemonetics from $85.00 to $88.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Barrington Research reiterated an “outperform” rating and set a $86.00 price target on shares of Haemonetics in a research report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $77.10.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.